EPIGRAL1,149.50

Epigral Limited

· Chemicals
₹ CrorePeersYASHOGUJALKALIFCLFOSECOINDVISHNUTATVAGALAXYSURFJUBLCPLMcap ₹4,959 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Revenue Growth+32.2-0.9
EBITDA Growth+47.7-20.2
EBIT Growth+61.7-31.0
Net Income Growth+82.7-7.2
EPS Growth+79.7-9.1
Total Assets Growth+12.8+11.2
Total Equity Growth+51.9+16.6
Cash from Operations Growth+10.8-1.1
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.